Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

17.07.2019 | short review | Ausgabe 3/2019

memo - Magazine of European Medical Oncology 3/2019

Checkpoint inhibitors in head and neck cancer

memo - Magazine of European Medical Oncology > Ausgabe 3/2019
Dr. Ilson Sepulveda, Rodrigo Ascui, A. Andrés Capizzano
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Head and neck cancer (HNC) are aggressive cancers and represents the sixth leading cancer by incidence worldwide. This kind of cancer constitutes about 3% of all newly diagnosed malignant tumors in humans, and this percentage is likely to increase in the future. Most common available treatment methods which include surgery, radiotherapy, and chemotherapy are associated with low survival outcomes in combination with substantial toxicities emphasize the necessity for novel treatment strategies.The combination immunotherapies represent a fundamental step in the progress towards improving responses, and immune checkpoint inhibitors will likely become the immunotherapeutic backbone of future cancer treatments.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3/2019

memo - Magazine of European Medical Oncology 3/2019 Zur Ausgabe